Drug therapy 1999: a critical review of therapeutics
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Buch |
Sprache: | English |
Veröffentlicht: |
New York
McGraw-Hill
1999
|
Schlagworte: | |
Online-Zugang: | Inhaltsverzeichnis |
Beschreibung: | XXXI, 488 Seiten |
ISBN: | 0071349901 |
Internformat
MARC
LEADER | 00000nam a2200000 c 4500 | ||
---|---|---|---|
001 | BV012571609 | ||
003 | DE-604 | ||
005 | 20180702 | ||
007 | t | ||
008 | 990521s1999 |||| 00||| eng d | ||
020 | |a 0071349901 |9 0-07-134990-1 | ||
035 | |a (OCoLC)42859766 | ||
035 | |a (DE-599)BVBBV012571609 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
049 | |a DE-20 | ||
050 | 0 | |a RM262 | |
082 | 0 | |a 615.1 |2 21 | |
084 | |a XI 1400 |0 (DE-625)152974:12905 |2 rvk | ||
100 | 1 | |a Gibaldi, Milo |e Verfasser |0 (DE-588)172096723 |4 aut | |
245 | 1 | 0 | |a Drug therapy 1999 |b a critical review of therapeutics |c Milo Gibaldi, Ph. D., School of Pharmacy, Department of Pharmaceutucs, University of Washington, Seattle, Washington |
264 | 1 | |a New York |b McGraw-Hill |c 1999 | |
300 | |a XXXI, 488 Seiten | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
650 | 4 | |a Pharmacology | |
650 | 4 | |a Chemotherapy | |
650 | 4 | |a Drug Therapy | |
650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Wirkung |0 (DE-588)4190021-2 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Evaluation |0 (DE-588)4071034-8 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Klinische Prüfung |0 (DE-588)4031192-2 |2 gnd |9 rswk-swf |
689 | 0 | 0 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
689 | 0 | 1 | |a Evaluation |0 (DE-588)4071034-8 |D s |
689 | 0 | |5 DE-604 | |
689 | 1 | 0 | |a Klinische Prüfung |0 (DE-588)4031192-2 |D s |
689 | 1 | |5 DE-604 | |
689 | 2 | 0 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
689 | 2 | 1 | |a Wirkung |0 (DE-588)4190021-2 |D s |
689 | 2 | |5 DE-604 | |
856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008537399&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
999 | |a oai:aleph.bib-bvb.de:BVB01-008537399 |
Datensatz im Suchindex
_version_ | 1804127220284784640 |
---|---|
adam_text | Contents
Preface xxxi
Chapter 1
New Drugs
Cardiovascular Disease
Clopidogrel (Plavix): A Rich Man s Aspirin 3
Glycoprotein Ilb/IIIa Receptor Blockers: Superaspirins for
Acute Coronary Syndromes 4
Lepirudin (Refludan) for Heparin Induced
Thrombocytopenia 6
Angiotensin II Receptor Antagonists for Hypertension 6
Fenoldopam (Corloplam) for Severe Hypertension 7
Fenofibrate (Tricor) for Elevated Triglyceride Levels 8
Cilostazol {Pletal): A New Drug for Intermittent
Claudication 9
Diabetes
Repaglinide (Prandin) for Type 2 Diabetes 11
Recombinant Glucagon for Hypoglycemia 12
Infectious Disease
Ribavirin Increases Effectiveness of Interferon in Hepatitis C 13
Anti HIV Drug for Chronic Hepatitis B 15
Trovafloxacin (Trovan): A New Fluoroquinolone for a Wide
Variety of Infections 16
Synercid: A Drug Combination for Resistant Organisms 16
Rifapentine (Priftin): New Treatment for Tuberculosis 17
Contents
Sustiva: Another NNRTI for the Treatment of HIV Infection 18
Abacavir (Ziagen): An NRTI Alternative to HIV Protease
Inhibitors 19
Inflammatory Disease
Hyaluronic Acid Derivatives for Osteoarthritis 21
Leflunomide (Arava) for Rheumatoid Arthritis 21
Mental Health
Citalopram (Celexa): A New SSRI for the Treatment of
Depression 23
Neurological Disease
Tolcapone (Tasmar): First COMT Inhibitor for Parkinson s
Disease 25
New Triptans for Migraine 26
Tiagabine (Gabitril) for Partial Seizures 28
Obesity
Sibutramine (Meridia) for Weight Reduction 30
Oncology
Implanted Wafers for Treatment of Brain Tumors 32
Irinotecan (Cctmptosar) for Colorectal Cancer 32
Valrubicin (Vatstar): A New Drug for Bladder Cancer 33
Alitretinoin Gel (Ptmretin) for Kaposi s Sarcoma 33
Cytarabine Liposome Injection (DepoCyt) for
Lymphomatous Meningitis 33
Pain Management
Fentanyl: An Old Drug in a New Form for Serious Pain 35
FDA Panel Recommends Approval for COX 2 Inhibitor
Celecoxib (Celebrex) 35 ,«
Contents
Respiratory Disease
Tobramycin for Inhalation as Treatment for Cystic Fibrosis 37
Montelukast {Singulair) for Adults and Children with Asthma 37
Women s Health
Raloxifene (Evista): A Designer Estrogen for the Prevention
of Osteoporosis 39
Estrogen/Progestin Transdermal Patch 41
Toremifene and Letrozole: Anti Estrogen Therapy for
Breast Cancer 42
Capecitabine (Xeloda): Oral Treatment for Metastatic
Breast Cancer 42
Men s Health
Viagra for Male Erectile Dysfunction 44
Propecia for the Prevention and Restoration of Hair Loss
in Men 52
Other Indications
Hydroxyurea in Sickle Cell Anemia 54
New Drugs for Bladder Control 55
Thalidomide (Thalomitt) for Leprosy Related Condition 56
Doxycycline for Periodontal Disease 57
Topical Brinzolamide for Glaucoma 59
Risedronate (Actonell) for Paget s Disease 59
Late Breaking Reports
Infectious Disease 59
Oncology 60
Pain Management 60
Respiratory Disease 60
Women s Health 61
Other Indications 61
Contents
Chapter 2
Drug Evaluation: Controlled
Clinical Studies
Cardiovascular Disease
Aspirin and Warfarin Prevent First Heart Attack 65
Long Term Oral Anticoagulant Therapy for Acute Coronary
Syndromes 67
Computer Guided Dosing of Warfarin Outperforms
Traditional Dosing 68
Ticlopidine (Ticlitt) Effective for Angioplasty but Adverse
Effects Limit Use 68
Abciximab (ReoPro) Shines in Angioplasty Trial 69
Hirudin and Enoxaparin Show Benefit in Unstable Angina 71
Addition of Enoxaparin Prevents Venous Thromboembolism
after Surgery 72
Limited Role for Drugs in Cardiac Arrest 73
Lower Limit of LDL Cholesterol Reduction Unresolved 73
Simvastatin versus Atorvastatin 75
Primary Prevention of Acute Coronary Events with a Statin 76
Pravastatin Prevents Morbidity and Mortality in All Patients
with Coronary Heart Disease 76
Atorvastatin (Lipitor) May Reduce Need for Coronary
Revascularization 78
ACE Inhibitors for Heart Failure: Dosing Issues 79
Spironolactone (Aldactone) Benefits Patients with Heart
Failure 80
Bisoprolol: A /3 Blocker for Heart Failure 80
New Studies May Change Treatment Guidelines for
Hypertension 81
Selecting the Right Antihypertensive Agent 83
Diabetes
Troglitazone in Patients with Type 2 Diabetes Mellitus 85
Multiple Benefits of ACE Inhibitors in Patients with Diabetes 86
Contents
Early, Intensive Insulin Therapy Preserves Islet Function in
Type 1 Diabetics 88
Intensive Glucose Control for Type 2 Diabetes 88
Tight Control of Blood Pressure for Type 2 Diabetes 91
Improved Glucose Control with Glipizide Realizes
Short Term Benefits 91
Gastrointestinal Disease
Prilosec versus Cytotec for NSAID Induced GI Ulcers 93
H Pylori Eradication of no Benefit for NSAID Induced
GI Ulcers 94
Infectious Disease
Zinc Not Effective for Common Cold in Children 96
Vitamin Supplements Decrease Adverse Pregnancy
Outcomes in HIV Infected Women 97
Short Term AZT Reduces Vertical Transmission of HIV 97
Initial Therapy of HIV Infection: Conservative or Aggressive? 99
Maintenance Therapy Fails to Maintain Suppression of
HIV Load 100
It s Not Just the Virus Stupid 101
Lamivudine for Chronic Hepatitis B 103
Acyclovir for Prevention of Ocular Herpes Infection 104
Oral Famciclovir for Suppression of Recurrent Genital Herpes 105
Inflammatory Disease
Budesonide and Mesalamine for Active Crohn s Disease 107
Mental Health
Old Versus New Antidepressants for Patients with Heart
Disease 108
Paroxetine (Paxil) for the Treatment of Social Anxiety
Disorder 109
Long Term Sertraline of Benefit for Chronic Depression 110
Contents
Neurological Disease
Excedrin Extra Strength to Treat Migraine Headache 111
Riboflavin to Prevent Migraine Headache 112
Best Treatment for Status Epilepticus 112
New Dosage Forms to Treat Acute Repetitive Seizures 113
Selegiline Levodopa Combination Increases Mortality
for Patients with Parkinson s Disease 114
Dopamine Agonist—Pramipexole—Reduces Tremor in
Parkinson s Disease 115
Donepezil (Aricept) Improves Cognition and Function in
Alzheimer Disease 115
Drug Therapy for Multiple Sclerosis 116
Obesity
Olestra and Gastrointestinal Symptoms 118
Oncology
Tamoxifen Reduces the Incidence of Breast Cancer 119
Aspirin and Colon Cancer 124
Optimizing Chemotherapy for Childhood Acute
Lymphoblastic Leukemia 125
Palliative for Prostate Cancer Offers No Benefit 126
Carboplatin Monotherapy as Effective as Combination
Therapy in Ovarian Cancer 126
Pain Management
Preemptive Analgesia Gives Mixed Results 128
Respiratory Disease
Inhaled Corticosteroids and COPD 129
Prolonged Corticosteroid Therapy Improves Acute
Respiratory Distress Syndrome 130
Montelukast (Sinjfulair) and Salmeterol {Serevent) for
Exercise Induced Asthma 131
Zafirlukast (Accolate) and Montelukast (Singulair) Show
Promise in Asthma 133
Contents
Nebulized Budesonide Compared with Intramuscular
Dexamethasone for Croup 134
Transplantation
Risk of Cancer in Kidney Allograft Recipients 135
Women s Health
Fosamax Prevents Bone Loss in Postmenopausal Women 137
Estrogen/Bisphosphonate Combination for Osteoporosis 138
Fluoride Decreases Vertebral Fracture Rates 139
Parathyroid Hormone Prevents Bone Loss in Women
Treated For Endometriosis 140
Aspirin Does Not Prevent Preeclampsia 140
Isosorbide Mononitrate for Cervical Ripening before
Abortion 141
Benefit of Emergency Contraception Available without a
Prescription 142
Better Tolerated and More Effective Emergency
Contraception 143
Bisphosphonate Reduces Risk of Breast Cancer Recurrence
and Mortality 144
Spermicide (Nonoxynol 9) Does Not Reduce Transmission
ofSTDs 144
Calcium Supplements Ameliorate PMS and May Provide
Other Benefits 145
Men s Health
Proscar Effective for Men with Enlarged Prostate Glands 148
Children s Health
Growth Hormone for Short Normal Girls 150
Sertraline (Zolofi) in Children and Adolescents with OCD 150
Health in the Elderly
Lowering Blood Pressure Prevents Dementia in the Elderly 152
Contents
Other Indications
Therapy to Ameliorate Steroid Induced Osteoporosis 154
Subcutaneous Compared with Intravenous Erythropoietin
in Hemodialysis 155
Tacrolimus for Atopic Dermatitis 156
Late Breaking Reports
Cardiovascular Disease 156
Gastrointestinal Disease 159
Pain Management 160
Women s Health 160
Other Indications 161
Chapter 3
Drug Evaluation: Other Studies
and Reports
Cardiovascular Disease
Statins for the Prevention of Stroke 165
High Dose Simvastatin Lowers Cholesterol and Triglycerides 166
Stopping Antihypertensive Medication May Pose Risks 166
/3 Blockers—Not First Line Therapy for Hypertension in
the Elderly 166
Heparin Therapy for Treatment of Acute MI in the Elderly 167
Long Term Benefit of a Thrombolytic Agent and Aspirin
after MI 167
New Indication for Aprotinin in Bypass Graft Surgery 168
Bleeding Risk Index May Improve Safety of Warfarin 168
Underuse of Warfarin in Patients with Atrial Fibrillation
and Ischemic Stroke 169
)3 Blockers in Chronic Heart Failure 169
Diabetes
Type 1 Diabetes, Weight Gain, and Coronary Artery Disease 170
Caution Needed in Prescribing Acarbose (Precose) 170
Contents
Gastrointestinal Disease
New Ten Day Regimens for Eradicating H pylori and
Peptic Ulcer 172
Proton Pump Inhibitors for Bleeding Peptic Ulcer 172
Infectious Disease
British Guidelines for Anti retroviral Treatment of
HIV Infection 173
Anti HFV Therapy Reduces Morbidity and Mortality 173
Treating STDs May Reduce Sexual Transmission of HIV 174
Eradicating HIV in the Central Nervous System 175
Managing Protease Inhibitor Related Lipid Abnormalities 175
Hydroxyurea May Benefit Patients with HIV Infection 176
Directly Observed Therapy for Tuberculosis 176
Optimizing the Dose of Interferon for Hepatitis C 177
Restriction of Cephalosporin Use Reduces Resistant
Klebsiella Infection 177
Influenza Vaccination Benefits Low Risk Elderly 178
Concerted Effort to Eliminate Trachoma 178
Inflammatory Disease
Corticosteroids for the Treatment of Rheumatoid Arthritis 180
Cytotoxic Agents and Cyclosporine for Autoimmune Disease 180
Mental Health
More Benefits of Current Generation of Antipsychotic Drugs 182
SSRI Antidepressants and Weight Gain 182
Obesity
Obesity Guidelines Caution on Drug Use 184
Oncology
Cyclosporine Improves Oral Therapy with Taxol 185
Arsenic Induces Complete Remission for a Form of
Leukemia 185
Contents
Respiratory Disease
Competing Inhaled Corticosteroids Not Equipotent 187
Women s Health
Hormone Replacement Therapy Decreases Risk of
Colorectal Cancer 188
Tamoxifen: Secondary Prevention of Breast Cancer 189
Chemotherapy for Early Breast Cancer Improves Survival 189
Estrogen Therapy: Effects on Cognitive Function
and Dementia 190
Estrogen Replacement Therapy and Breast Cancer Evidence 190
Understanding and Treating Premenstrual Syndrome 191
Oral Contraceptives and the Risk of Hereditary
Ovarian Cancer 192
Does Acetaminophen Protect Against Ovarian Cancer? 193
Progestin Only Oral Contraceptives May Increase the Risk
of Type 2 Diabetes 193
Cancer Risk in Women Exposed to Diethylstilbestrol
in Utero 194
Hormone Replacement Therapy Reduces Risk of
Hip Fracture 194
Meeting Reports Hold Promise for the Treatment of
Osteoporosis 195
Estrogen Replacement Therapy and Type 2 Diabetes 195
Birth Control Pill for Acne 196
Teenage Girls Favor Depot Contraceptive 196
Low Dose OCs Do Not Increase the Risk of a
Heart Attack 197
Sex Differences in Viral Load and Progression to AIDS 197
Erythromycin Poses Greater Risk of Arrhythmias
for Women 198
Men s Health
Treatment of Sexual Deviation in Men 199
Aging Men Lose Testosterone 199
Aging Men Also Lose Estrogen and Develop Osteoporosis 200
Contents
Children s Health
Growth Hormone Therapy for Children 201
Survey Reveals Alarming Overuse of Antibiotics in Children 201
Antidepressants Pose Low Risk to Fetus 202
Cesarean Delivery May Reduce Risk of Vertical Transmission
of HIV 202
Risk Factors for Perinatal Transmission of HIV in Women
Receiving AZT 203
Abbreviated AZT Regimens Reduce Risk of Perinatal
HIV Transmission 203
Attempted Abortion with Misoprostol Increases the Risk of
Birth Defect 204
Pamidronate for Osteogenesis Imperfecta 204
Health in the Elderly
Vitamin D Deficiency in the Sick and Elderly 206
No Advantage of SSRIs over TCAs in Risk of Falls and
Hip Fracture 206
Inhaled Steroids and Cataracts in the Elderly 207
Other Studies and Reports
Nasal Corticosteroids or Nonsedating Antihistamines for
Allergic Rhinitis 208
Liver Disease Selectively Decreases Activity of Drug
Metabolizing Enzymes 208
Secretin Improves Behavior in Children with Autism 209
Adverse Drug Effects
Acetaminophen is a Risk Factor for Excesssive Warfarin
Anticoagulation 210
Regular Use of Aspirin May Increase the Risk of Stroke 211
Ticlopidine May Result in TTP after Stenting 211
Grapefruit Juice, Statins, and Adverse Effects 212
Drug for CMV Retinitis May Lead to Renal Failure 212
Benzodiazepines and Other CNS Drugs Impair Driving Skills 212
Contents
Over the Counter NSAIDs May Cause Liver Damage
in Patients with Hepatitis C 213
Side Effects of Alendronate (Fosamax) 213
Safety of Long Term Use of Nicotine Replacement
Products Questioned 214
Risk of Intracranial Bleed after TPA for Acute MI 214
Pharmacoeconomics
Introduction 216
Preventing AIDS Related Opportunistic Infections:
Economic Implications 216
Cost Effectiveness of STD Treatment to Prevent HIV
Infection in Africa 217
Cost Effectiveness of Drugs to Treat Schizophrenia 217
Cost Effectiveness of Smoking Cessation Services 218
The Cost of Gastroesophageal Reflux Disease 219
Cyclosporine (Neoral) Faces Competition 220
America s Soaring Drug Costs 220
FTC Challenges Major Generic Drug Manufacturer s Prices 223
Late Breaking Reports
Cardiovascular Disease 223
Infectious Disease 225
Other Studies and Reports 225
Adverse Drug Effects 225
Pharmacoeconomics 226
Chapter 4
In the Pipeline
Cardiovascular Disease
Treatment of Ischemic Stroke 231
Endothelin Antagonists for the Treatment of
Cardiovascular Disease 232
Will Oral Glycoprotein Ilb/IIIa Inhibitors Replace Aspirin? 233
Novel Mechanism to Lower Cholesterol 234
Contents
Gastrointestinal Disease
Isomer of Cisapride (Propulsid) Could Be Safer and
Expand Indications 236
Single Isomer Version of Omeprazole Better than
Omeprazole 236
Infectious Disease
New Pharmaceuticals May Mean Safer Sex for Women 237
New Combination of Antiviral Drugs May Simplify
HIV Therapy 238
New Protease Inhibitor Offers Less Frequent Dosing 239
The Next Wave of Anti HIV Agents 239
Treatment of Kaposi s Sarcoma 241
New Drugs for the Treatment of Colds and Flu 241
Oxazolidinone Antimicrobials for Multidrug
Resistant Infections 242
Mental Health
New Indications for SSRI Antidepressants 244
New Antidepressants Will Challenge Market Leaders 244
New Way to Treat Schizophrenia 246
Neurological Disease
Anti Cancer Drug Benefits Patients with Multiple Sclerosis 248
Obesity
Orlistat (Xenical): Novel Drug for Weight Loss 249
Strategies and Potential Targets for the Treatment
of Obesity 251
Oncology
Photodynamic Therapy for Cancer 252
Pain Management
New Nonopioid Analgesic 253
Enhancing the Effects of Morphine 253
New NSAIDs: An Array of Benefits without Stomach Damage 253
Contents
Respiratory Disease
Combination Therapy for Asthma 257
Substance Abuse
Blocking Glutamate May Help Alcoholics and Drug Addicts 258
Transplantation
New and Important Immunosuppressant on the Horizon 259
Women s Health
Combined Hormone Replacement for Postmenopausal
Women 260
Other Indications
Modafinil for Sleep Disorders 261
Therapeutic Potential of Botulinum Toxin 261
New Strategies for Male Contraception 262
Late Breaking Reports
Infectious Disease 262
Mental Health 263
Pain Management 263
Substance Abuse 264
Chapter 5
Vaccines
Introduction
New Products
Intranasal Flu Vaccine for Children 268
Rotavirus Vaccine Now a Reality 269
Lyme Disease Vaccine: Ready for the Summer of 1999 271
Contents
In the Pipeline
Melanoma Vaccine: Early Stages 273
Multicomponent Malaria Vaccine Fails to Prevent Infection 274
DNA Vaccines Show Promise 274
FDA Authorizes Phase III Testing for HIV Vaccine 277
Other Strategies to Develop a Vaccine for HIV Infection 278
A Vaccine Against Pneumococcal Meningitis and
Bacteremia 279
Other Issues
Vaccine Liability and Safety 281
Activists Challenge Safety of Hepatitis B Vaccination Effort 282
CDC Recommends Major Tuberculosis Vaccine Effort 283
Late Breaking Reports
New Products 283
Other Issues 284
Chapter 6
Biotechnology
New Products
Platelet Derived Growth Factor (PDGF) for Diabetic
Foot Ulcers 287
Herceptin, a Monoclonal Antibody for Breast Cancer 287
Infliximab (Remicade) for Crohn s Disease 289
Palivizumab (Synagis) Prevents RSV Disease in Children 291
Monoclonal Antibodies to Prevent Transplant Rejection 291
Vitravene: First Antisense Agent Clears FDA Panel 292
Advisory Committee Supports Approval of Stem Cell
Growth Factor 293
FDA Approves Enbrel for Rheumatoid Arthritis 294
Contents
In the Pipeline
Telomeres, Telomerase, Aging, and Cancer 297
Nerve Growth Factor for Cornea] Ulcers and Diabetic
Neuropathy 298
Replication Competent Viruses for Tumors 299
P53 Based Strategies to Keep Cancer in Check 300
Blocking Oncogenes 301
Monoclonal Antibodies for the Treatment of Cancer 302
Matrix Metalloproteinases (MMPs) for the Treatment
of Cancer 303
New Therapies to Prevent Diabetic Retinopathy 303
A Role for Pro Inflammatory Cytokines in Heart Failure? 304
Administering the Products of Biotechnology 304
Replenishing Blood Components 306
Small Molecule Drugs Substituting for Large Ones 308
Leptin: The Antiobesity Hormone 308
Leptin Triggers Angiogenesis 309
A New Target for AntifflV Therapy 310
The Search for Effective Strategies against Septic Shock 311
Monoclonal Antibody to CD4 in Chronic Severe Asthma 312
Pharmacologic Manipulation of Gene Expression 313
Therapeutic Strategies
Antisense 315
Apoptosis
Restoring a Cell s Ability to Die 317
Angiogenesis
Introduction 320
Angiogenesis and Tumor Progression 320
Therapeutic Inhibition of Angiogenesis in Neoplastic
Disease 321
Angiogenesis Inhibitors and the Media 323
Therapeutic Augmentation of Angiogenesis 325
Contents
Gene Therapy
Delivering Genes to Target Sites Still a Major Hurdle 328
In Utero Gene Therapy 330
Monoclonal Antibodies
Human Antibodies by Design 332
Pharmacogenomics
Genetic Strategies to Individualize Drug Therapy 334
Late Breaking Reports
New Products 335
In the Pipeline 336
Therapeutic Strategies 337
Chapter 7
Alternative Medicine
Introduction
Clinical Studies
Vitamin E Cuts Risk of Prostate Cancer 342
Multivitamins, Folate, and Colon Cancer in Women 343
Vitamins, Homocysteine Levels, and the Risk of
Cardiovascular Disease 343
Ginkgo for Dementia 345
Garlic Has No Effect on Elevated Cholesterol Levels 346
DHEA for Aging 347
Selenium May Protect Against Prostate Cancer 347
Supplementing Fatty Acids in Infant Formula Enhances
Problem Solving 349
Cancer Cure Sweeps Italy 349
Contents
Regulatory Issues
Huperzine for Alzheimer s Disease: End Run
Around FDA 352
FDA Challenges Marketing of Herb to Lower Cholesterol 353
Medicated Skin Preparations—Drugs or Cosmetics? 354
Sleep Aid Found to be Contaminated 354
The Safety of Dietary Supplements 355
Other Reports
St. John s Wort for Depression 358
Kava: The Next Herbal Superstar 359
Saw Palmetto for Enlarged Prostate 359
Soy Foods for Perimenopausal Estrogen Deficiency 360
Androstenedione and Athletic Performance 360
Horse Chestnut Seed Extract for Varicose Veins 361
Brand Name Companies Want a Piece of the Dietary
Supplement Market 361
The Made in Italy Answer to the Problem of
Impotence . 362
Update on Vitamin Supplements 362
JAMA Devotes November to Alternative Medicine 363
Late Breaking Reports
Clinical Trials 364
Regulatory Issues 364
Other Reports 365
Chapter 8
Regulatory Actions and Issues
Drug Recalls and Warnings
Drug Interactions Drive Calcium Channel Blocker
from Market 369
Contents
Long Term Use of Bromfenac (Dumct) Results in
Serious Toxicity 371
Isotretinoin May Promote Depression 373
FDA Wants New Drug Interaction Warnings for
Astemizole (Hismanal) 373
Safety Concerns Limit the Use of Cisapride (Propulsid) 374
FDA Seeks to Remove Cancer Warning on Estrogen/
Progestin Products 375
Prolonged QT Interval Worries Regulators 375
Thrombotic Thrombocytopenic Purpura Warning on
Ticlopidine (Ticlid) Label 376
Pediatric Warning on Inhaled Corticosteroids 376
Authorities Restrict Use of Cough/Cold Preparations 378
FDA Cautions about Use of Albumin in Seriously
111 Patients 378
FDA Halts Distribution of Drug Used to Sterilize Women 379
Alcohol Warnings for OTC Analgesics 379
Regulatory Issues
Promotion of Pharmaceutical Products 380
FDA to Require Pediatric Data on Drug Products 384
Drug Industry Proposes Guidelines on
Pharmacoeconomic Analysis 385
Generic Drug Industry Wants Rule Changes 386
FDA Not Protecting the Public, Say Critics 389
FDA Establishes Post Marketing Office 389
Citizen s Group Petitions FDA on Inaccurate Patient
Information 390
Administration Nominates New FDA Commissioner 390
Late Breaking Reports
Regulatory Actions 392
Regulatory Issues 392
Contents
Chapter 9
Biomedical Ethics
New Marketing Practices Threaten Privacy 397
Pharmaceutical Companies and Academic Researchers 398
Protecting Human Research Subjects 400
AIDS Vaccine Trials in the Third World 403
Placebo Controlled Clinical Trials 404
Treatment of Patients with Terminal Disease 405
Drug Companies Find Novel Ways to Thwart Generic
Competition 406
Rationing Scarce Drugs 407
Late Breaking Reports
Questionable Anti Generic Strategy Could Affect Merger Plan 408
Protecting Human Research Subjects: An Update 408
Chapter 10
Therapeutic Controversies
and Dilemmas
Cardiovascular Disease
Hypertension: Dramatically Undertreated 411
The Treatment of Hypertension: Is There a Role for
Calcium Channel Blockers? 411
Underprescribing of /3 Blockers after a Heart Attack 414
TPA for the Treatment of Stroke 416
Infectious Disease
Prophylactic Acyclovir and the Risk of Developing Drug
Resistant Herpesvirus 420
Treatment of Infection for Secondary Prevention of
Cardiovascular Events 420
Contents
Drug Resistant Microbes 422
Principles of Therapy of HIV Infection and Guidelines
for Use of Antiretroviral Agents 423
Understanding and Treating HIV Infection: A Survey 425
Oncology
High Dose Chemotherapy and Autologous Bone Marrow
Transplantation for Breast Cancer 433
Rationing Taxol in the UK 435
Pain Management
Undertreatment of Pain Remains a Serious Problem 436
Substance Abuse
Methadone Clinics Challenged in New York City 438
Women s Health
Birth Control by Means of Emergency Contraception 440
Low Dose Estrogen Oral Contraceptives and the Risk of
Heart Attack 441
Safety of Third Generation Oral Contraceptives 442
Mifepristone (RU 486) and Misoprostol to Terminate
Unwanted Pregnancy 444
Hormone Replacement Therapy and Secondary Prevention
of Heart Disease 445
Children s Health
Drugs in Pregnancy 448
Mandatory HIV Testing of Pregnant Women 449
Adverse Drug Effects
Safety of Troglitazone in Patients with Type 2 Diabetes 451
Are Drug Reactions A Major Casue of Death? 452
Litigation on Recalled Diet Drugs 454
Contents
Other Issues
Optimizing Clinical Trials May Reduce Applicability 457
Failure to Adhere to Prescribed Drug Regimen 458
Late Breaking Reports
Substance Abuse 460
Index 463
|
any_adam_object | 1 |
author | Gibaldi, Milo |
author_GND | (DE-588)172096723 |
author_facet | Gibaldi, Milo |
author_role | aut |
author_sort | Gibaldi, Milo |
author_variant | m g mg |
building | Verbundindex |
bvnumber | BV012571609 |
callnumber-first | R - Medicine |
callnumber-label | RM262 |
callnumber-raw | RM262 |
callnumber-search | RM262 |
callnumber-sort | RM 3262 |
callnumber-subject | RM - Therapeutics and Pharmacology |
classification_rvk | XI 1400 |
ctrlnum | (OCoLC)42859766 (DE-599)BVBBV012571609 |
dewey-full | 615.1 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 615 - Pharmacology and therapeutics |
dewey-raw | 615.1 |
dewey-search | 615.1 |
dewey-sort | 3615.1 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01831nam a2200481 c 4500</leader><controlfield tag="001">BV012571609</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20180702 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">990521s1999 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0071349901</subfield><subfield code="9">0-07-134990-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)42859766</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV012571609</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM262</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1400</subfield><subfield code="0">(DE-625)152974:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Gibaldi, Milo</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)172096723</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug therapy 1999</subfield><subfield code="b">a critical review of therapeutics</subfield><subfield code="c">Milo Gibaldi, Ph. D., School of Pharmacy, Department of Pharmaceutucs, University of Washington, Seattle, Washington</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">McGraw-Hill</subfield><subfield code="c">1999</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXXI, 488 Seiten</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkung</subfield><subfield code="0">(DE-588)4190021-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Evaluation</subfield><subfield code="0">(DE-588)4071034-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Evaluation</subfield><subfield code="0">(DE-588)4071034-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Wirkung</subfield><subfield code="0">(DE-588)4190021-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008537399&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008537399</subfield></datafield></record></collection> |
id | DE-604.BV012571609 |
illustrated | Not Illustrated |
indexdate | 2024-07-09T18:29:53Z |
institution | BVB |
isbn | 0071349901 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008537399 |
oclc_num | 42859766 |
open_access_boolean | |
owner | DE-20 |
owner_facet | DE-20 |
physical | XXXI, 488 Seiten |
publishDate | 1999 |
publishDateSearch | 1999 |
publishDateSort | 1999 |
publisher | McGraw-Hill |
record_format | marc |
spelling | Gibaldi, Milo Verfasser (DE-588)172096723 aut Drug therapy 1999 a critical review of therapeutics Milo Gibaldi, Ph. D., School of Pharmacy, Department of Pharmaceutucs, University of Washington, Seattle, Washington New York McGraw-Hill 1999 XXXI, 488 Seiten txt rdacontent n rdamedia nc rdacarrier Pharmacology Chemotherapy Drug Therapy Arzneimittel (DE-588)4003115-9 gnd rswk-swf Wirkung (DE-588)4190021-2 gnd rswk-swf Evaluation (DE-588)4071034-8 gnd rswk-swf Klinische Prüfung (DE-588)4031192-2 gnd rswk-swf Arzneimittel (DE-588)4003115-9 s Evaluation (DE-588)4071034-8 s DE-604 Klinische Prüfung (DE-588)4031192-2 s Wirkung (DE-588)4190021-2 s HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008537399&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
spellingShingle | Gibaldi, Milo Drug therapy 1999 a critical review of therapeutics Pharmacology Chemotherapy Drug Therapy Arzneimittel (DE-588)4003115-9 gnd Wirkung (DE-588)4190021-2 gnd Evaluation (DE-588)4071034-8 gnd Klinische Prüfung (DE-588)4031192-2 gnd |
subject_GND | (DE-588)4003115-9 (DE-588)4190021-2 (DE-588)4071034-8 (DE-588)4031192-2 |
title | Drug therapy 1999 a critical review of therapeutics |
title_auth | Drug therapy 1999 a critical review of therapeutics |
title_exact_search | Drug therapy 1999 a critical review of therapeutics |
title_full | Drug therapy 1999 a critical review of therapeutics Milo Gibaldi, Ph. D., School of Pharmacy, Department of Pharmaceutucs, University of Washington, Seattle, Washington |
title_fullStr | Drug therapy 1999 a critical review of therapeutics Milo Gibaldi, Ph. D., School of Pharmacy, Department of Pharmaceutucs, University of Washington, Seattle, Washington |
title_full_unstemmed | Drug therapy 1999 a critical review of therapeutics Milo Gibaldi, Ph. D., School of Pharmacy, Department of Pharmaceutucs, University of Washington, Seattle, Washington |
title_short | Drug therapy 1999 |
title_sort | drug therapy 1999 a critical review of therapeutics |
title_sub | a critical review of therapeutics |
topic | Pharmacology Chemotherapy Drug Therapy Arzneimittel (DE-588)4003115-9 gnd Wirkung (DE-588)4190021-2 gnd Evaluation (DE-588)4071034-8 gnd Klinische Prüfung (DE-588)4031192-2 gnd |
topic_facet | Pharmacology Chemotherapy Drug Therapy Arzneimittel Wirkung Evaluation Klinische Prüfung |
url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008537399&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
work_keys_str_mv | AT gibaldimilo drugtherapy1999acriticalreviewoftherapeutics |